Wells Fargo & Company MN boosted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 1.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 197,630 shares of the company’s stock after buying an additional 3,353 shares during the quarter. Wells Fargo & Company MN owned approximately 0.50% of Omnicell worth $14,210,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Victory Capital Management Inc. acquired a new position in Omnicell during the 3rd quarter worth about $494,000. Braun Stacey Associates Inc. lifted its stake in shares of Omnicell by 3.9% in the 3rd quarter. Braun Stacey Associates Inc. now owns 196,085 shares of the company’s stock valued at $14,098,000 after purchasing an additional 7,370 shares during the period. EULAV Asset Management acquired a new position in shares of Omnicell in the 3rd quarter valued at about $1,086,000. Russell Investments Group Ltd. lifted its stake in shares of Omnicell by 5.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 430,736 shares of the company’s stock valued at $30,970,000 after purchasing an additional 22,182 shares during the period. Finally, Conestoga Capital Advisors LLC lifted its stake in shares of Omnicell by 12.4% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 2,060,908 shares of the company’s stock valued at $148,179,000 after purchasing an additional 227,685 shares during the period.

In related news, CFO Peter J. Kuipers sold 5,574 shares of the business’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $68.87, for a total value of $383,881.38. Following the completion of the sale, the chief financial officer now directly owns 51,542 shares of the company’s stock, valued at approximately $3,549,697.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director James T. Judson sold 5,000 shares of the business’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $71.18, for a total value of $355,900.00. Following the completion of the sale, the director now directly owns 29,952 shares of the company’s stock, valued at $2,131,983.36. The disclosure for this sale can be found here. Insiders sold a total of 19,267 shares of company stock valued at $1,309,116 over the last ninety days. 3.71% of the stock is currently owned by corporate insiders.

OMCL has been the topic of a number of recent analyst reports. Benchmark boosted their price objective on Omnicell from $66.00 to $79.00 and gave the company a “buy” rating in a research note on Friday, October 5th. BidaskClub downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 4th. Craig Hallum boosted their price objective on Omnicell from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, September 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $80.00 price objective (up from $70.00) on shares of Omnicell in a research note on Thursday. Finally, Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a research note on Monday, August 13th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. Omnicell currently has a consensus rating of “Buy” and a consensus target price of $72.13.

Shares of NASDAQ:OMCL opened at $70.59 on Friday. The stock has a market capitalization of $2.96 billion, a PE ratio of 392.17, a price-to-earnings-growth ratio of 4.46 and a beta of 0.99. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.32 and a current ratio of 1.78. Omnicell, Inc. has a 1 year low of $39.75 and a 1 year high of $79.48.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, October 25th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.40 by $0.09. Omnicell had a return on equity of 7.91% and a net margin of 6.11%. The business had revenue of $204.27 million during the quarter, compared to analyst estimates of $203.48 million. On average, equities research analysts forecast that Omnicell, Inc. will post 1.42 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/wells-fargo-company-mn-buys-3353-shares-of-omnicell-inc-omcl/2668291.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

See Also: How to read a candlestick chart

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.